Treatments against multiple sclerosis, the next scandal by sleeping on the prices of medicines in the United States? Elijah Cummings and Peter Welch, both democrats members of the House of Representatives, questioned the practices of several pharmaceutical companies and have decided to launch an investigation.
These two used actions to reduce the prices of medicines considered exorbitant have sent letters to the seven pharmaceutical companies (Sanofi, Novartis, Roche, Bayer, Teva, etc.). In these missives, they ask for explanations to understand the rapid inflation of the prices of treatments for multiple sclerosis. To be clear, the two politicians are seeking to determine if the pharmaceutical companies have increased their prices at the same time, or not.
Cost of treatment annual: 78.000 dollars on average
On average, the price of a therapy against multiple sclerosis, a disease that affects more than two million people in the world, are passed down from 16,000 to 78,000 dollars per year between 2004 and 2016, estimates the National Multiple Sclerosis Society, an organization dedicated to the research against multiple sclerosis. Questioned on the subject, Roche has stated that it is necessary to reverse the trend of increases in this therapeutic area, reports Reuters, while ensuring to offer its molecule Ocrevus at a price 20% lower than the average.
This is not the first therapeutic area for which the laboratories are invectivés on their practices of fixing prices. In the beginning of the year, a group of patients filed an action against several laboratories alleging that agreement to inflate prices of insulins.
>> Read also : Diabetes mellitus: the take-off of the price of the insulin concerned in the United States